Overview

A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC

Status:
Recruiting

Trial end date:
2026-09-30

Target enrollment:

Participant gender:

Summary

This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of adebelizumab combined with carboplatin/Cisplatin plus (+) etoposide and concurrent radiotherapy in the first-line treatment of patients with extensive stage oligometastatic small cell lung cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Nanfang Hospital, Southern Medical University

Collaborator:

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Treatments:

Carboplatin
Etoposide